The Genitourinary (GU) Cancer Program at Penn Medicine provides treatment for cancers of the genitourinary (GU) tract including bladder cancer, prostate cancer, kidney cancer, testicular cancer and certain rare tumors.
Penn Medicine has one of the largest and most experienced testicular cancer programs in the United States. Penn faculty have been instrumental in developing chemotherapy treatments for a variety of GU cancers.
A Multidisciplinary Approach to Care
Cancer specialists within the GU Cancer Program have dedicated their clinical and research careers to improving the ability to diagnose and treat GU cancer.
Penn hematologists/oncologists are part of multidisciplinary teams of specialists, including urologists, radiation and surgical oncologists, pathologists and radiologists who are all trained to treat the entire person – not just the disease.
All specialists practice in the Perelman Center for Advanced Medicine. Their close proximity to each other ensures that patients receive cutting-edge collaborative care.
At Penn Medicine, patients with GU cancer also benefit from services and programs offered through the Abramson Cancer Center, including nutrition, psychosocial counseling, support groups and education.
Abramson Cancer Center
Genitourinary (GU) Cancer Services
Hematology/oncology services for bladder cancer, prostate cancer, kidney cancer, testicular cancer, and other rare tumors within the GU Cancer Program include:
- Treatment and disease management
- Follow-up care
- Survivorship programs
A LIVESTRONG™ Center of Excellence
Today, people with GU cancer are living longer and better than ever before. More than 90 percent of testicular cancer patients survive their cancer. The issues patients may face after cancer treatment are unique. Their health and wellness after cancer treatment is now recognized as a distinct phase of patient care.
The Abramson Cancer Center is only one of eight LIVESTRONG™ centers in the United States, and is the only LIVESTRONG™ Survivorship Center of Excellence in the Philadelphia region. The program focuses on survivorship, and develops survivorship plans for patients who have completed cancer treatment.
The Penn Difference
- David Vaughn, MD, oversees one of the largest testicular cancer programs in the country.
- Naomi Haas, MD, is chair of national clinical trials in kidney cancer.
- Penn's GU Cancer Program has an active early drug development program that brings molecularly targeted and other novel therapies to the clinical setting in early phase 1 clinical trials.
- Oncologists in the GU Cancer Program at Penn Medicine focus specifically on GU cancer.
- Hematologists/oncologists in the GU Cancer Program are leaders of cutting-edge clinical trials in kidney, bladder and testicular cancer.
- Penn hematologists/oncologists are researching the genetic components of testicular cancer susceptibility, and have enrolled more than 600 patients in studies to find the genes that underlie susceptibility to this disease.
Genitourinary (GU) Cancer Team
Hematologists/oncologists within the Genitourinary (GU) Cancer Program include:
Today, more and more people are surviving cancer. It is because of clinical trials, many of which are conducted at Penn Medicine, that patients are benefiting from breakthrough therapies and treatments. These new advances in cancer treatment are occurring every day, giving patients hope that even greater discoveries lie ahead.